MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 471079 | Name: RD162
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RD162 is an analogue of Enzalutamide and is used to assess androgen receptor (AR) involvement, with applications in treating prostate cancer.

Chemical Structure

RD162
RD162
CAS#915087-27-3

Theoretical Analysis

MedKoo Cat#: 471079

Name: RD162

CAS#: 915087-27-3

Chemical Formula: C22H16F4N4O2S

Exact Mass: 476.0900

Molecular Weight: 476.45

Elemental Analysis: C, 55.46; H, 3.39; F, 15.95; N, 11.76; O, 6.72; S, 6.73

Price and Availability

Size Price Availability Quantity
5mg USD 440.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RD162; RD-162; RD 162;
IUPAC/Chemical Name
4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl-benzamide
InChi Key
JPQFGMYHKSKKGW-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16F4N4O2S/c1-28-18(31)15-6-5-14(10-17(15)23)30-20(33)29(19(32)21(30)7-2-8-21)13-4-3-12(11-27)16(9-13)22(24,25)26/h3-6,9-10H,2,7-8H2,1H3,(H,28,31)
SMILES Code
O=C(NC)C1=CC=C(N(C(N(C2=CC=C(C#N)C(C(F)(F)F)=C2)C3=O)=S)C43CCC4)C=C1F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 476.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. PMID: 19359544; PMCID: PMC2981508. 2: Moll JM, Kumagai J, van Royen ME, Teubel WJ, van Soest RJ, French PJ, Homma Y, Jenster G, de Wit R, van Weerden WM. A bypass mechanism of abiraterone- resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Prostate. 2019 Jun;79(9):937-948. doi: 10.1002/pros.23799. Epub 2019 Apr 24. PMID: 31017696; PMCID: PMC6593470. 3: Moll JM, Teubel WJ, Erkens SE, Jozefzoon-Agai A, Dits NF, van Rijswijk A, Jenster GW, van Weerden WM. Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer. Front Oncol. 2022 Jun 13;12:877613. doi: 10.3389/fonc.2022.877613. PMID: 35769712; PMCID: PMC9234122. 4: Makkonen H, Kauhanen M, Jääskeläinen T, Palvimo JJ. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol. 2011 Jan 1;331(1):57-65. doi: 10.1016/j.mce.2010.08.008. Epub 2010 Aug 20. PMID: 20728506. 5: Bessede T, Beuzeboc P, Bladou F, Fizazi K, Mongiat-Artus P, Villers A. Stratégies thérapeutiques du cancer de la prostate résistant à la castration [Strategies in castration-resistant prostate cancer]. Prog Urol. 2011 Mar;21 Suppl 2:S68-71. French. doi: 10.1016/S1166-7087(11)70015-X. PMID: 21397833. 6: Ji C, Guha M, Zhu X, Whritenour J, Hemkens M, Tse S, Walker GS, Evans E, Khan NK, Finkelstein MB, Callegari E, Obach RS. Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model. Chem Res Toxicol. 2020 Jan 21;33(1):211-222. doi: 10.1021/acs.chemrestox.9b00247. Epub 2019 Oct 9. PMID: 31538772.